BRPI0512757B1 - Método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição - Google Patents
Método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição Download PDFInfo
- Publication number
- BRPI0512757B1 BRPI0512757B1 BRPI0512757-2A BRPI0512757A BRPI0512757B1 BR PI0512757 B1 BRPI0512757 B1 BR PI0512757B1 BR PI0512757 A BRPI0512757 A BR PI0512757A BR PI0512757 B1 BRPI0512757 B1 BR PI0512757B1
- Authority
- BR
- Brazil
- Prior art keywords
- liposomes
- dda
- fact
- tdb
- vaccine
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 66
- 229960005486 vaccine Drugs 0.000 title claims abstract description 36
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 13
- 239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 10
- 229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 10
- 230000006641 stabilisation Effects 0.000 title claims abstract description 9
- 238000011105 stabilization Methods 0.000 title claims abstract description 9
- 241000606161 Chlamydia Species 0.000 title claims abstract description 5
- 201000004792 malaria Diseases 0.000 title claims abstract description 5
- 239000013011 aqueous formulation Substances 0.000 title claims abstract description 4
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 49
- 239000002671 adjuvant Substances 0.000 claims abstract description 42
- 125000002091 cationic group Chemical group 0.000 claims abstract description 25
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 13
- 230000000890 antigenic effect Effects 0.000 claims abstract description 9
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 38
- 150000002632 lipids Chemical class 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 26
- 230000002209 hydrophobic effect Effects 0.000 claims description 19
- -1 dimethyl dihydrate Chemical class 0.000 claims description 18
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 15
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 14
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 14
- 238000010348 incorporation Methods 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 12
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 11
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims description 11
- 239000000232 Lipid Bilayer Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- 229930182470 glycoside Natural products 0.000 claims description 9
- 150000002772 monosaccharides Chemical group 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 150000002016 disaccharides Chemical class 0.000 claims description 7
- 150000002338 glycosides Chemical class 0.000 claims description 7
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 239000003012 bilayer membrane Substances 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229920000392 Zymosan Polymers 0.000 claims description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims description 2
- 230000005660 hydrophilic surface Effects 0.000 claims description 2
- 229960002109 tuberculosis vaccine Drugs 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- LZTCQASULATCDM-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;acetate Chemical compound CC([O-])=O.CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC LZTCQASULATCDM-UHFFFAOYSA-M 0.000 claims 1
- 238000009513 drug distribution Methods 0.000 claims 1
- 229940124735 malaria vaccine Drugs 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 59
- 238000009472 formulation Methods 0.000 abstract description 42
- 230000003053 immunization Effects 0.000 abstract description 13
- 238000002649 immunization Methods 0.000 abstract description 13
- 239000012736 aqueous medium Substances 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract description 4
- 239000012467 final product Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 3
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 82
- 239000002245 particle Substances 0.000 description 28
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 21
- 239000007983 Tris buffer Substances 0.000 description 20
- 230000028993 immune response Effects 0.000 description 20
- 239000010408 film Substances 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 230000007704 transition Effects 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000001294 propane Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 239000000693 micelle Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 239000002691 unilamellar liposome Substances 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000003147 glycosyl group Chemical group 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- 241000589567 Brucella abortus Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940056450 brucella abortus Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- NGZSKXNBTXMPPX-UHFFFAOYSA-N dimethyl-bis(octadec-1-enyl)azanium Chemical compound CCCCCCCCCCCCCCCCC=C[N+](C)(C)C=CCCCCCCCCCCCCCCCC NGZSKXNBTXMPPX-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000013554 lipid monolayer Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 125000000647 trehalose group Chemical group 0.000 description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GWUNZLSWZMWKSN-UHFFFAOYSA-N Hydroxymyristate Chemical compound CCCCCCCCCCCCCC(=O)OO GWUNZLSWZMWKSN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 description 1
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- HNJDESMFGVZUQY-UHFFFAOYSA-M dimethyl-bis(octadec-1-enyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCC=C[N+](C)(C)C=CCCCCCCCCCCCCCCCC HNJDESMFGVZUQY-UHFFFAOYSA-M 0.000 description 1
- TXVXMXYVMYKENA-UHFFFAOYSA-M dimethyl-bis(octadec-1-enyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCC=C[N+](C)(C)C=CCCCCCCCCCCCCCCCC TXVXMXYVMYKENA-UHFFFAOYSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005064 octadecenyl group Chemical group C(=CCCCCCCCCCCCCCCCC)* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 150000002943 palmitic acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Além disso, a patente descreve que o carregamento retardado dos lipossomos pré-formados e armazenados é possível por uma combinação de gradientes de concentração e o processo de desidratação-reidratação.
Glicolipídios à base de glicerol: esses lipídios consistem em uma fração mono- ou oligossacarídeo ligada glicosidicamente ao grupo hidroxila do glicerol, que pode ser acilado (ou alquilado) com um ou dois ácidos graxos. Além disso, esses glicolipídios podem ser sem carga e, portanto, freqüentemente são chamados de glicoglicerolipídios neutros, ou podem conter um grupo sulfato ou fosfato.
Glicolipídios à base de ceramidas: glicoesfingolipídios foram, de acordo com a estrutura da fração carboidrato, divididos em glicoesfingolipídios neutros contendo um grupo glicosila não substituído e glicoesfingolipídios ácidos contendo um grupo glicosila com um grupo carboxila, sulfato ou fosfato ácido.
Lipopolissacarídeos (LPS): esses compostos complexos são os antígenos endotóxicos encontrados nas paredes celulares de bactérias Gram-negativas (S-lipopolissacarídeos). A parte lipídica (Lipídio A) forma um complexo com um polissacarídeo mediante uma ligação glicosídica. O Lipídio A consiste em uma estrutura principal de b-1,6-glucosaminil-glucosamina com dois grupos fosfoéster na posição 1 da glucosamina I e na posição 4 da glucosamina II. A posição 3 da glucosamina II forma a ligação glicosídica ácido lábil com o polissacarídeo de cadeia longa. Os outros grupos são substituídos (em Escherichia) com ácidos graxos hidroxilados, como hidroximiristato (dois ligados em éster e dois ligados em amida) e ácidos graxos normais (laurato). Um lipopolissacarídeo particularmente preferido desta invenção são os derivados monofosforila de lipídio A (MPL) , que são não tóxicos e têm excelentes propriedades adjuvantes.
Glicosídeos de esteróis: essa família consiste em uma unidade carboidrato ligada ao grupo hidroxila de uma molécula de esterol. Determinou-se que a fração esterol era composta por vários esteróis: colesterol, campesterol, estigmasterol, sitosterol, brassicasterol e diidrositosterol. A fração açúcar é composta por glicose, xilose e mesmo arabinose.
Glicosídeos de ácidos ou álcoois graxos: um grande número de glicolipídios simples é encontrado em bactérias, leveduras e em organismos inferiores (esponjas). Esses compostos são compostos por uma fração glicosila (uma ou várias unidades) ligada a um grupo hidroxila de um álcool graxo ou de um ácido hidróxi graxo ou a um grupo carboxila de um ácido graxo (ligação éster). Esses compostos freqüentemente possuem interessantes propriedades fisicas ou biológicas. Alguns deles são produzidos industrialmente por suas propriedades detergentes (alquil glicosídeos).
Uma cadeia acila se refere a um grupo alquil-OC(O), em que o grupo alquila é conforme anteriormente descrito.
Uma cadeia de ácido graxo se refere a uma cadeia de hidrocarboneto saturada ou insaturada, ramificada ou não ramificada, de grupos alquila ou acila.
Vacina protéica: uma composição de vacina compreendendo um polipeptídio (ou pelo menos uma parte imunogênica dele) ou polipeptídio de fusão.
Vacinas recombinantes vivas: a expressão do antígeno relevante em uma vacina em um microorganismo ou vírus não patogênico. Os exemplos bem conhecidos desses microorganismos incluem Mycobacterium bovis BCG, Salmonella e Pseudomonas, e os exemplos de vírus incluem o vírus da varíola bovina e adenovirus.
Figura 2. Fotografia digital de formulações de DDA a 10 mM depois de 2 meses de armazenamento a 4°C. (Amostra 02) contém 16% molar de TDB, (Amostra 03) contém 12,5% molar de TDB, (Amostra 04) contém 6% molar de TDB, (Amostra 05) contém 2,5% molar de TDB, (Amostra 06) contém 0,5% molar de TDB, e uma amostra de referência contendo apenas DDA. Está claro nessa ilustração que as suspensões contendo TDB são mais homogêneas e sem precipitados.
Figura 3 . Termogramas DSC de lipossomos multilamelares compostos por DDA-B com concentrações crescentes de TDB (de cima para baixo) , obtidos a uma taxa de varredura de 30 C/h. Os lipossomos foram dispersados em tampão Tris a 10 mM com pH 7,4. Os termogramas ilustram claramente que o TDB está inserido nas membranas de lipossomos de DDA.
Figura 4. Termogramas DSC de lipossomos multilamelares compostos por DDA-B e TDB com concentrações crescentes do antígeno Ag85B-ESAT-6 (de cima para baixo, obtidos a uma taxa de varredura de 30 C/h. Os lipossomos foram dispersados em tampão Tris a 10 mM com pH 7,4. Os termogramas ilustram claramente que a temperatura de transição de fase não se altera pela incorporação de um antígeno nos lipossomos.
Figura 5. Desenvolvimento temporal do tamanho de partícula médio de lipossomos de DDA contendo 0 mol% (-♦-), 6% molar (-▲-), 11% molar (-★-) e 20% molar (-■-) de TDB. Os lipossomos foram dispersados em tampão Tris a 10 mM ajustado a pH 7,4. Um aumento significado é observado para lipossomos de DDA sem TDB após 14 dias.
Figura 6A. Desenvolvimento temporal do tamanho de partícula médio de lipossomos de DDA (-♦-) e lipossomos de DDA contendo 11% molar de TDB, preparados pelo método térmico aquoso (-▲-), 11% molar de TDB, preparados pelo método de película (-■-). Os lipossomos foram dispersados em tampão Tris a 10 mM ajustado a pH 7,4. Um aumento significativo foi observado para lipossomos de DDA e para lipossomos de DDA/TDB preparados pelo método térmico aquoso após 14 dias.
Figura 7A. Desenvolvimento temporal do tamanho de partícula médio de lipossomos de DDA contendo 11% molar de TDB (-■-), 10% (p/v) de trealose (-⚫-) e 10% (p/v) de sacarose (-X-). Os lipossomos foram dispersados em tampão Tris a 10 mM ajustado a pH 7,4. Os lipossomos de DDA contendo trealose e sacarose se agregaram em um grau que tornou impossível fazer medições adicionais por PCS após 14 dias.
Figura 7Β. Fotografia digital de formulações de DDA a 10 mM contendo 10% (p/v) de trealose e 11% molar de TDB, respectivamente, após 14 dias de armazenamento a 4°C. Observou-se uma grave agregação na formulação contendo trealose.
Figura 8. A análise SDS-PAGE do sobrenadante e pelota ressuspendida de Ag85B-ESAT-6 ultracentrifugado de vacinas prontas para o uso finais foi realizada para visualizar a adsorção de antígeno nos lipossomos catiônicos.
Figura 9. Liberação de IFN-gama de linfócitos sangüíneos isolados de camundongos C57BI/6j imunizados com Ag85B-ESAT- 6/DDA/TDB preparado conforme descrito no exemplo 1 desta invenção ou Ag85B-ESAT-6/DDA/TDB preparado conforme descrito por Holten-Andersen et al. (2004) . Os linfócitos foram isolados 1 semana após a terceira imunização e estimulados com Ag85B-ESAT-6 a 5 µg/mL.
Figura 10. Liberação de IFN-gama e IL-5 de linfócitos sangüíneos isolados de camundongos C57BI/6j imunizados com 2 µg de Ag85B-ESAT-6/DDA/TDB ou Ag85B-ESAT-6 em 500 µg de alúmen. Os linfócitos sangüíneos foram isolados 1 semana após a terceira imunização e reestimulados in vitro com 5 µg/mL de Ag85B-ESAT-6.
Figura 11A. Liberação de IFN-gama de esplenócitos isolados de camundongos BALB/C imunicados com 2 µg de Ag85B-ESAT-6 em 250 µg de DDA/50 µg de TDB, 100 µg de Poli IC, ou 250 µg de DDA/50 µg de TDB/100 µg de Poli IC. Os esplenócitos foram isolados três semanas após a terceira imunização e reestimulados in vitro com 5 µg/mL de Ag85B-ESAT-6.
Figura 11B. Ligeração de IFN-gama de linfócitos sangüíneos isolados de camundongos BALB/C imunizados com 2 µg de Ag85B-ESAT-6 em 250 µg de DDA/50 µg de TDB, 25 µg de MDP, ou 250 µg de DDA/50 µg de TDB/25 µg de MDP. As células sangüíneas foram isoladas três semanas após a terceira imunização e reestimuladas in vitro com 5 µg/mL de Ag85B-ESAT-6.
Figura 12. Desenvolvimento temporal do tamanho de partícula médio de lipossomos de DDA (-♦-) e lipossomos de DD A contendo 11% molar de TDB (-⚫-), 11% molar de lactocil ceramida (-★-) e 11% molar de α-galactosil ceramida (-X-). Os lipossomos foram dispersados em tampão Tris a 10 mM ajustado a pH 7,4. Observou-se um aumento significativo para lipossomos de DDA sem glicolipídio após 14 dias, indicando que outros glicolipídios, além do TDB, podem estabilizar DDA.
Tabela 1. Relaciona uma gama de formulações de adjuvantes preparadas de acordo com a presente invenção.
Tabela 2. Descreve a estabilidade em 2 meses de uma gama de diferentes formulações de adjuvantes.
Três varreduras ascendentes consecutivas da amostra de 0,34 mL foram realizadas a 30 C/h. As amostras foram equilibradas durante 50 min à temperatura de partida.
A estabilidade de partículas de DDA-B contendo concentrações crescentes de TDB são preparadas pelo método de película e foi medida por medições de espalhamento de luz dinâmico utilizando-se um Malvern ZetaSizer 4 (Malvern Instruments Ltd. UK) . Formulações de partículas de DDA-B com 0, 6, 11 e 20% molar de TDB incorporados foram dispersadas em tampão Tris a 10 mM com pH 7,4 no dia 0. As medições foram feitas nos dias 0, 14, 28, 42, 56 e 105 após a preparação (Figura 5). A comparação da estabilidade de tamanho de partícula no tempo mostra que a incorporação de TDB estabiliza as partículas de DDA-B e impede que se agreguem. Em contraste, a formulação com apenas DDA agregou após poucos dias de armazenamento a 4°C, e, após o dia 42, nenhuma medição de tamanho de partícula adicional era possível devido à agregação. Esses dados sustentam a impressão visual das formulações de DDA e DDA/TDB mostradas na Figura 2.
A análise SDS-PAGE do sobrenadante e pelota ressuspendida de Ag85B-ESAT-6 ultracentrifugado de vacinas prontas para o uso finais foi realizada para visualizar a adsorção de antígeno nos lipossomos catiônicos. O adjuvante compreendia lipossomos catiônicos compostos por DDA estabilizados pela incorporação de 15% molar do glicolipídio TDB. A concentração de Ag85B-ESAT-6 (PM 45 kDa) na vacina final era de 40, 80, 160 e 200 microgramas/mL, e as concentrações de DDA e TDB eram de 10 e 0,6 mM, respectivamente. As vacinas foram ultracentrifugadas (100.000 g) durante 30 min, e a análise SDS-PAGE foi realizada no sobrenadante e na pelota ressuspendida no volume original de tampão Tris (Figura 8). Uma amostra de referência contendo 50 microgramas de Ag85B-ESAT-6 por mL foi carregada na raia 1, e um marcador de peso molecular foi carregado na raia 2. As bandas de proteínas foram visualizadas por coloração com Coomassie. Nenhuma banda visível foi observadas nas raias carregadas com os sobrenadantes, ao passo que bandas claras a um peso molecular aproximado de 45 kDa foram observadas nas raias carregadas com as pelotas ressuspendidas, indicando que todo ou quase todo o antígeno é adsorvido nos lipossomos catiônicos.
É geralmente aceito que adjuvantes têm alguma seletividade pela indução de uma certa classe de resposta imune. Como a importância de uma liberação de citocina Thl baseada na produção de IFN-γ foi demonstrada como essencial na resistência a TB (Flynn et al. , 1993; Cooper et al. , 1993), lipossomos de DDA-B contendo 20% molar de TDB foram preparados conforme descrito no exemplo 1 desta invenção e misturados com uma solução em tampão Tris de Ag85B-ESAT-6 em uma vacina final. A concentração na vacina final era de 250 pg de DDA, 100 pg de TDB e 2 µg de Ag85B-ESAT-6. Para comparação, incluiu-se outra vacina, que era composta pelas mesmas quantidades de DDA e TDB, mas preparada conforme anteriormente descrito em DMSO (Holten-Andersen et al., 2004), isto é, sem incorporação d eTDB nos lipossomos pelo método de película. Camundongos foram imunizados três vezes, e, uma semana após a 3a vacinação, as respostas imunes específicas de células sangüíneas foram investigadas (Figura 9) . Observou-se uma resposta muito maior após a imunização com DDA/TDB preparado pelo método de película, em comparação com o método anteriormente descrito, demonstrando que a preparação de DDA/TDB pelo método de película intensifica o efeito adjuvante, em comparação com uma simples misturação de DDA/TDB.
Tabela 5. Títulos médios de anticorpos específicos para antígeno no soro de camundongos imunizados com Ag85B-ESAT-6a Níveis de IgG específicos para Ag85B-ESAT-6 5 semanas após a primeira imunização, conforme medidos por ELISA
Recentemente, ligantes para receptores do tipo Toll (TLR) foram considerados alvos atraentes para inclusão em novas formulações de adjuvantes. Para investigar o efeito da incorporação de outros componentes imunoestimuladores, isto é, ligantes TLR, na formulação de DDA/TDB, os camundongos foram imunizados com 2 µg de Ag85B-ESAT-6 em 250 µg de DDA/50 µg de TDB e imunomoduladores selecionados. Esses incluíam 100 µg de Poli IC (ácido poliinosínico-policitidílico, Sigma Aldrich), adicionados a lipossomos de DDA-TDB pré-formados, que é sabidamente um ligante para TLR3, assim como 25 µg de muramil dipeptídio (MDP), que confere ativação de TLR2/TLR4. MDP foi incluído na película lipídica de DDA-TDB antes da hidratação.
Claims (21)
- Método de estabilização de lipossomos catiônicos de lipídios catiônicos em formulações aquosas, caracterizado pelo fato de que compreende:
a incorporação de glicolipídios nos lipossomos, em que os referidos lipídios catiônicos são compostos de amônio quaternário anfifílicos e os glicolipídios são incorporados de maneira estável na bicamada lipídica com sua fração hidrofóbica incorporada na região hidrofóbica da membrana da bicamada e sua fração do grupo principal polar orientada para a superfície hidrofílica da membrana. - Método de estabilização de lipossomos, de acordo com a reivindicação 1, caracterizado pelo fato de que cada composto de amônio quaternário anfifílicos tem uma ou duas cadeias alifáticas,
e em que cada uma das cadeias alifáticas compreende de 12 a 20 átomos de C. - Método de estabilização de lipossomos, de acordo com a reivindicação 2, caracterizado pelo fato de que os compostos de amônio quaternário anfifílicos são selecionados a partir do grupo que consiste em:
brometo de dimetildioctadecilamônio (DDA-B), cloreto de dime-tildioctadecilamônio (DDA-C), sulfato, fosfato ou sal acetato de dimetildioctadecilamônio (DDA-X), dimetildioctadecenodiamenodiamônio (brometo de dimetildioctadecilamônio) DODA-C), sulfato, fosfato, composto acetato de dimetildioctadecenilamônio (DODA-X), 1,2-dioleoil-3-trimetilamônio propano; (DOTAP), dioleoil-3-dimetilaminopropano (DODAP) e N-[1-(2,3-dioleiloxi)propil]-N,N,N-trimetilamônio (DOTMA). - Método de estabilização de lipossomos, de acordo com qualquer uma das reivindicações 1 a 3, caracterizado pelo fato de que os glicolipídios são glicosídeos acilados, cada um formado por uma ou até três cadeias de hidrocarbonetos alifáticos ligadas a um ou dois resíduos de monos-sacarídeos na porção de açúcar, em que as cadeias de hidrocarbonetos ali-fáticos compreendem cada uma de 12 a 20 átomos de C.
- Método de estabilização de lipossomos, de acordo com a reivindicação 4, caracterizado pelo fato de que cada um dos glicolipídios contém um dissacarídeo com duas cadeias acila,
em que as cadeias acila compreendem de 15 a 90 átomos de C. - Método de estabilização de lipossomos, de acordo com a reivindicação 5, caracterizado pelo fato do que os glicolipídios são 6,6'-dibeenato de alfa,alfa'-trealose (TDB) ou 6,6'-dimicolato de alfa,alfa'-trealose (TDM).
- Método de estabilização de lipossomos, de acordo com qualquer uma das reivindicações 1 a 6, caracterizado pelo fato de que a porcentagem molar de glicolipídio é de 0,5 a 95% molar.
- Método de estabilização de lipossomos, de acordo com qualquer uma das reivindicações 1 a 7, caracterizado pelo fato de que a porcentagem molar de glicolipídeo é de 2,5 a 20% molar.
- Método de estabilização de lipossomos, de acordo com qualquer uma das reivindicações 1 a 8, caracterizado pelo fato de que a porcentagem molar de glicolípido de 5 a 18% molar.
- Produto de lipossomo, caracterizado pelo fato de que é estabilizado pelo método como definido em qualquer uma das reivindicações 1 a 9.
- Produto de lipossomo, de acordo com a reivindicação 10, caracterizado pelo fato de que um composto antigênico é encapsulado nos lipossomos.
- Produto de lipossomo, de acordo com a reivindicação 11, caracterizado pelo fato de que um antígeno é adsorvido ou acoplado cova-lentemente ao lipossomo.
- Produto de lipossomo, de acordo com qualquer uma das reivindicações 10 a 12, caracterizado pelo fato de que os lipossomos são estabilizados por 6,6'-dibeenato de alfa,alfa'-trealose (TDB) ou 6,6'-dimicolato de alfa,alfa'-trealose (TDM).
- Produto de lipossomo, de acordo com qualquer uma das reivindicações 10 a 13, caracterizado pelo fato de que é para uso em distribuição de medicamentos.
- Produto de lipossomo, de acordo com qualquer uma das reivindicações 10 a 13, caracterizado pelo fato de que é para uso como um adjuvante.
- Adjuvante de vacina, caracterizado pelo fato de que compreende o produto de lipossomo como definido em qualquer uma das reivindicações 10 a 15.
- Adjuvante de vacina, de acordo com a reivindicação 16, caracterizado pelo fato de que ainda compreende um modulador imune selecionada a partir do grupo que consiste em:
monofosforil lipídio (MPL), derivados de monofosforil lipídeo A (MPL), ácido poliinosínico policitidílico (poli-IC), miramil dipeptídeo (MDP), análogos de miramil dipeptídeo (MDP), zimosan, RNA de filamento duplo (dSRNA), DC-chol, CpG oligoidesoxinucleotídeos e tamoxifeno. - Adjuvante da vacina, de acordo com a reivindicação 17, caracterizado pelo fato de que o referido modulador imune é selecionado a partir do grupo que consiste em:
monofosforil lipídeo A (MPL), ácido poliinosínico policitidílico (po-li-IC), miramil dipeptídeo (MDP), zimosano, RNA de filamento duplo (dSRNA), DC-chol, CpG oligoidesoxinucleotídeos e tamoxifeno. - Adjuvante de vacina, de acordo com qualquer uma das reivindicações 16 a 18, caracterizado pelo fato de que ainda compreende miramil dipeptídeo (MDP) e/ou ácido poliinosínico policitidílico (poli-IC).
- Adjuvante de vacina, de acordo com qualquer uma das reivindicações 16 a 19, caracterizado pelo fato de que é para uso em uma vacina contra clamídia, malária ou tuberculose.
- Vacina contra clamídia, malária ou tuberculose, caracterizada pelo fato de que compreende o adjuvante como definido qualquer uma das reivindicações 16 a 19.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401070 | 2004-07-07 | ||
DKPA200401070 | 2004-07-07 | ||
PCT/DK2005/000467 WO2006002642A2 (en) | 2004-07-07 | 2005-07-05 | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0512757A BRPI0512757A (pt) | 2008-04-08 |
BRPI0512757B1 true BRPI0512757B1 (pt) | 2021-04-06 |
BRPI0512757B8 BRPI0512757B8 (pt) | 2021-05-25 |
Family
ID=34982425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512757A BRPI0512757B8 (pt) | 2004-07-07 | 2005-07-05 | método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1765289B1 (pt) |
JP (1) | JP4987704B2 (pt) |
KR (1) | KR101275837B1 (pt) |
CN (1) | CN1980638B (pt) |
AT (1) | ATE406874T1 (pt) |
AU (1) | AU2005259685B2 (pt) |
BR (1) | BRPI0512757B8 (pt) |
CA (1) | CA2572985C (pt) |
DE (1) | DE602005009535D1 (pt) |
DK (1) | DK1765289T3 (pt) |
ES (1) | ES2315880T3 (pt) |
PL (1) | PL1765289T3 (pt) |
PT (1) | PT1765289E (pt) |
SI (1) | SI1765289T1 (pt) |
WO (1) | WO2006002642A2 (pt) |
ZA (1) | ZA200701043B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2402023A1 (en) | 2006-06-28 | 2012-01-04 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
EP2695608B1 (en) | 2006-10-03 | 2016-11-23 | Arbutus Biopharma Corporation | Lipid containing formulations |
WO2009003474A1 (en) | 2007-06-29 | 2009-01-08 | Statens Serum Institut | The use of monomycolyl glycerol (mmg) as an adjuvant |
AU2009241645B2 (en) * | 2008-05-02 | 2014-07-17 | Blink Therapeutics Limited | Products and methods for stimulating an immune response |
CN102325875B (zh) * | 2009-01-08 | 2018-04-10 | 阿尔伯爱因斯坦医学有限公司 | 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用 |
CN102482666B (zh) * | 2009-07-06 | 2017-02-08 | 变异生物技术公司 | 制备囊泡的方法和由其产生的制剂 |
BR112012033751B1 (pt) * | 2010-07-02 | 2021-06-01 | Intervet International B.V. | Composição de vacina e processo para produzir a composição de vacina |
WO2013004234A2 (en) | 2011-07-04 | 2013-01-10 | Statens Serum Institut | Methods for producing liposomes |
US20140045913A1 (en) * | 2011-12-12 | 2014-02-13 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising combination of cationic lipid |
TWI594767B (zh) * | 2011-12-12 | 2017-08-11 | 協和醱酵麒麟有限公司 | 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子 |
JP2016175841A (ja) * | 2013-08-02 | 2016-10-06 | 三郎 斎藤 | リポソームと、細胞障害性t細胞活性を誘導するワクチン組成物 |
KR20190009840A (ko) * | 2013-09-19 | 2019-01-29 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
US20170216430A1 (en) * | 2014-08-04 | 2017-08-03 | Nitto Denko Corporation | Immune-induction-promoting composition including nuclear receptor ligand, and vaccine pharmaceutical composition |
DK3325015T3 (da) * | 2015-07-20 | 2021-07-05 | Zoetis Services Llc | Liposomale adjuvanssammensætninger |
CN114657147B (zh) * | 2022-01-27 | 2023-12-01 | 安徽智飞龙科马生物制药有限公司 | 一种生物材料的保护剂及其应用 |
CN115068602B (zh) * | 2022-08-22 | 2022-11-01 | 北京华诺泰生物医药科技有限公司 | 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108934A (en) * | 1983-11-30 | 1992-04-28 | Kabushiki Kaisha Toshiba | Quantitative immunoassay utilizing liposomes |
JP2714972B2 (ja) * | 1988-02-02 | 1998-02-16 | 千葉製粉株式会社 | リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤 |
JPH03249561A (ja) * | 1990-02-28 | 1991-11-07 | Toshiba Corp | 免疫分析試薬 |
JPH0482824A (ja) * | 1990-07-23 | 1992-03-16 | Nippon Oil & Fats Co Ltd | リポソーム及び水中油型エマルション |
JPH0616688A (ja) * | 1992-06-30 | 1994-01-25 | Nippon Oil & Fats Co Ltd | 脂肪酸糖エステル |
JP3329554B2 (ja) * | 1993-03-10 | 2002-09-30 | 千葉製粉株式会社 | 乾燥小胞体 |
JP3884488B2 (ja) * | 1993-03-10 | 2007-02-21 | 千葉製粉株式会社 | オリゴ糖脂質 |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
JPH0925287A (ja) * | 1995-07-13 | 1997-01-28 | Eisai Co Ltd | 合成脂質 |
JPH09110722A (ja) * | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
US6183774B1 (en) * | 1996-01-31 | 2001-02-06 | Collaborative Laboratories, Inc. | Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
GB9808268D0 (en) * | 1998-04-17 | 1998-06-17 | Imp College Innovations Ltd | Compound |
GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
WO2003000227A2 (en) * | 2001-06-25 | 2003-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparation of vesicles loaded with biological material and different uses thereof |
-
2005
- 2005-07-05 SI SI200530467T patent/SI1765289T1/sl unknown
- 2005-07-05 CA CA2572985A patent/CA2572985C/en active Active
- 2005-07-05 WO PCT/DK2005/000467 patent/WO2006002642A2/en active Application Filing
- 2005-07-05 ES ES05756461T patent/ES2315880T3/es active Active
- 2005-07-05 KR KR1020077002648A patent/KR101275837B1/ko active IP Right Review Request
- 2005-07-05 BR BRPI0512757A patent/BRPI0512757B8/pt active IP Right Grant
- 2005-07-05 AT AT05756461T patent/ATE406874T1/de active
- 2005-07-05 PT PT05756461T patent/PT1765289E/pt unknown
- 2005-07-05 EP EP05756461A patent/EP1765289B1/en active Active
- 2005-07-05 PL PL05756461T patent/PL1765289T3/pl unknown
- 2005-07-05 DE DE602005009535T patent/DE602005009535D1/de active Active
- 2005-07-05 AU AU2005259685A patent/AU2005259685B2/en active Active
- 2005-07-05 DK DK05756461T patent/DK1765289T3/da active
- 2005-07-05 CN CN200580022926XA patent/CN1980638B/zh active Active
- 2005-07-05 JP JP2007519615A patent/JP4987704B2/ja active Active
-
2007
- 2007-02-05 ZA ZA200701043A patent/ZA200701043B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005259685B2 (en) | 2010-04-08 |
BRPI0512757B8 (pt) | 2021-05-25 |
ATE406874T1 (de) | 2008-09-15 |
BRPI0512757A (pt) | 2008-04-08 |
ZA200701043B (en) | 2007-12-27 |
EP1765289A2 (en) | 2007-03-28 |
EP1765289B1 (en) | 2008-09-03 |
PL1765289T3 (pl) | 2009-02-27 |
SI1765289T1 (sl) | 2009-02-28 |
JP2008505131A (ja) | 2008-02-21 |
CA2572985A1 (en) | 2006-01-12 |
JP4987704B2 (ja) | 2012-07-25 |
WO2006002642A3 (en) | 2006-05-18 |
DE602005009535D1 (de) | 2008-10-16 |
CA2572985C (en) | 2014-04-22 |
WO2006002642A2 (en) | 2006-01-12 |
DK1765289T3 (da) | 2008-12-15 |
CN1980638B (zh) | 2011-10-12 |
KR20070051847A (ko) | 2007-05-18 |
PT1765289E (pt) | 2008-12-05 |
AU2005259685A1 (en) | 2006-01-12 |
KR101275837B1 (ko) | 2013-06-18 |
ES2315880T3 (es) | 2009-04-01 |
CN1980638A (zh) | 2007-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7749520B2 (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
BRPI0512757B1 (pt) | Método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição | |
Albertsen et al. | The role of lipid components in lipid nanoparticles for vaccines and gene therapy | |
US20190201340A1 (en) | Methods for producing liposomes | |
Frezard | Liposomes: from biophysics to the design of peptide vaccines | |
Davidsen et al. | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses | |
US5709879A (en) | Vaccine compositions containing liposomes | |
JP5971945B2 (ja) | カチオン性脂質の鏡像異性体による免疫応答の刺激 | |
US20200345641A1 (en) | Lipid nanoparticles | |
JP2502234B2 (ja) | リポソ―ム含有ワクチン組成物 | |
JPH11512712A (ja) | 生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物 | |
ES2807607T3 (es) | Métodos para proporcionar virosomas con adyuvante y virosomas con adyuvante obtenibles de esta manera | |
Lendemans et al. | Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid | |
US20110287087A1 (en) | Modified cationic liposome adjuvans | |
JP7082110B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット | |
WO2016194685A1 (ja) | アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 | |
Kaur et al. | Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells | |
ES2234152T3 (es) | Vectores de antigenos en forma de vesiculas multilamelares. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |